Analyst Brian Cheng of J.P. Morgan maintained a Buy rating on Immunovant (IMVT – Research Report), with a price target of $46.00.Invest with ...

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) reached a new 52-week low on Monday after an insider sold shares in the ...

It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic ...

which can occur with a condition such as myasthenia gravis or muscular dystrophy. They may also order a blood test to see if an underlying condition (such as Graves' disease) is causing your ...

According to GlobalData, Phase III drugs for Graves’ Ophthalmopathy have ... demyelinating polyneuropathy (CIDP), Myasthenia Gravis, systemic sclerosis, primary Sjogren's syndrome, thyroid eye disease ...

Vyvgart is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who ... antibody-associated vasculitis (ANCA Vasculitis), Graves' ophthalmopathy (thyroid eye disease, ...

Teprotumumab (Tepezza), an insulin-like growth factor type 1 receptor antagonist, was approved for treatment of thyroid eye disease in 2020 ... disorders such as Guillain-Barre syndrome, myasthenia ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...